Open access · US-GOV via ClinicalTrials.gov Clinical trial

Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above After a Two-dose Schedule

Authors not listed

Chinese Academy of Medical Sciences · 2021

Stem-cell exhaustion Human Randomized controlled trial

Abstract

To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule of Institute of Medical Biology Chinese Academy of Medical Sciences SARS-CoV-2 inactivated vaccine.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-19 MST

Cite this

APA

Anonymous. (2021). Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above After a Two-dose Schedule. <em>Chinese Academy of Medical Sciences</em>. https://clinicaltrials.gov/study/NCT05164731

Vancouver

Anonymous. Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above After a Two-dose Schedule. Chinese Academy of Medical Sciences. 2021.

BibTeX

@misc{anon2021Clinic, title = {Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above After a Two-dose Schedule}, author = {Anonymous}, journal = {Chinese Academy of Medical Sciences}, year = {2021}, }